A published report says Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal.
An attorney for the state of Arkansas has asked jurors to hold a Johnson & Johnson subsidiary financially liable for allegedly concealing risks associated with its anti-psychotic drug Risperdal.
Texas prosecutors say drug maker Johnson & Johnson and some of its subsidiaries schemed to plunder hundreds of millions of dollars from the state Medicaid program by overstating the safety of an anti-psychotic drug and should be forced to repay that money plus penalties.